Fortress Biotech, Inc. (FBIO)

Market Cap	77.66M
Revenue (ttm)	59.30M
Net Income (ttm)	-24.05M
Shares Out	29.75M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,630
Open	2.490
Previous Close	2.520
Day's Range	2.460 - 2.610
52-Week Range	1.325 - 4.200
Beta	1.51
Analysts	Strong Buy
Price Target	16.50 (+532.18%)
Earnings Date	Nov 12, 2025

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: FBIO
• Website: https://www.fortressbiotech.com

Financial Performance

In 2024, Fortress Biotech's revenue was $57.68 million, a decrease of -31.76% compared to the previous year's $84.51 million. Losses were -$55.89 million, -18.61% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 532.18% from the latest price.

Price Target

$16.5

(532.18% upside)

Analyst Consensus: Strong Buy